References
- Furst DE. The rational use of methotrexate in rheumatoid arthritis and other rheumatic diseases. Br J Ftheumatol 1997;36:1196–204.
- American College of Ftheumatology Subcommittee on Rheuma-toid Arthritis Guidelines. Guidelines for the management of rheu-matoid arthritis. 2002 update. Arthritis Rheum 2002;46:328–46.
- Pincus T, Ferraccioli G, Sokka T, Larsen A, Rau R, Kushner I, et al. Evidence from clinical trials and long-term observational stud-ies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. Ftheu-matology 2002;41:1346–56.
- Jones G, Halbert J, Crotty M, Shanahan EM, Batterham M, Ahern M. The effect of treatment on radiological progression in rheuma-toid arthritis: a systemic review of randomized placebo-controlled trials. Ftheumatology 2003;42:6–13.
- Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
- Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985;312:818–22.
- Furst DE, Koehnke R, Burmeister LF, Kohler J, Cargill I. Increas-ing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. J Ftheumatol 1989;16:313–20.
- Barrera P, van der Maas A, van Ede AE, Kiemeney BALM, Laan FtFJM, van de Putte LBA, et al. Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-a antibody compared with methotrexate in long-standing rheuma-toid arthritis. Ftheumatology 2002;41:430–9.
- Dougados M, Combe B, Cantagrel A, Goupille P, Olive P, Schattenkirchner M, et al. Combination therapy in early rheuma-toid arthritis: a randomized, controlled, double-blind 52-week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis 1999;58:220–5.
- Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predict-ing response to treatment in rheumatoid arthritis. The importance of disease duration. Arthritis Rheum 2000;43:22–9.
- Hoekstra M, van Ede AE, Haagsma CJ, van de Laar MAF, Huizinga TWJ, Kruijsen MWM, et al. Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:423–6.
- Aletaha D, Stamm T, Kapral T, Ebert G, Grisar J, Machold KP, et al. Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study. Ann Rheum Dis 2003;62:944–51.
- Weinblatt ME, Maier AL, Fraser PA, Coblyn JS. Long-term prospective study of methotrexate in rheumatoid arthritis: con-clusion after 132 months of therapy. J Ftheumatol 1998;25:238–42.
- Suzuki Y, Noguchi A, Tajima C, Uehara R, Ide M, Ichikawa Y, et al. Clinical relapse of rheumatoid arthritis (escape phenomenon) during low-dose methotrexate therapy. Ryumachi 1998;38:6–13.